際際滷

際際滷Share a Scribd company logo

Trials in npx

Download as PPTX, PDF
H
Harihar Nath Tiwari

This document discusses treatment options for nasopharyngeal carcinoma. It notes that rates of the cancer vary significantly around the world. Surgical intervention is challenging due to the anatomic location. As a result, radiotherapy alone or combined with chemotherapy are the primary treatments. A previous meta-analysis found that adding chemotherapy to radiotherapy improves overall survival, particularly with concomitant (simultaneous) chemotherapy and radiotherapy. This study aims to update that meta-analysis and separately analyze the benefit of concomitant plus adjuvant chemotherapy. Survival curves are presented comparing radiotherapy alone versus combined with chemotherapy. The analysis confirms benefits of adding chemotherapy to radiotherapy, especially with concomitant administration, but the benefits of adjuvant chemotherapy require further assessment.

1 of 59
Download to read offline
NPC Treatment and clinical Trials Nasopharyngeal carcinoma is an uncommon cancer in most parts of the world. The age- adjusted incidence rate (per 100,000 people per year) among men ranges from 0.6 in the United States and Japan to 5.4 in Algeria, 5.8 in the Philippines,11.0 in Singapore, 17.2 among Eskimos, Indians, and Aleuts in Alaska to 17.8 and 26.9 in Hong Kong and Guangdong Province in Southern China, respectively.
Because of the anatomic locationproximity to critical structures surgical exposure and tumor resection with sufficient margins have been very challenging. Primary surgical intervention was rare after the 1950s for these reasons, with surgical interventions employed mainly for biopsy to gain histologic confirmation and salvage therapy for persistent or recurrent cancer. Primary treatment since has typically employed radiotherapy (RT) alone and, more recently, in combination with chemotherapy.
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
Trials in npx
A previous individual patient data meta- analysis by the Meta-Analysis of Chemotherapy in Nasopharynx Carcinoma (MAC-NPC) collaborative group to assess the addition of chemotherapy to radiotherapy showed that it improves overall survival in nasopharyngeal carcinoma. This benefit was restricted to patients receiving concomitant chemotherapy and radiotherapy
The aim of this study was to update the meta-analysis, include recent trials, and to analyse separately the benefit of concomitant plus adjuvant chemotherapy
Survival curves for overall survival in trials investigating CRT,and CRT Plus ACT
Survival curves for PFS in trials investigating CRT and CRT plus ACT
Survival curves for (A) OS and (B) PFS in CCRT And CCRT And ACT
conclusion this individual patient data meta-analysis confirms the benefits associated with the addition of chemotherapy to radiotherapy in nasopharyngeal carcinoma; the greatest benefit was found in the groups with concomitant administration. The benefits of the addition of adjuvant chemotherapy in the context of concomitant chemo-radiation still need further assessment.
Trials in npx
THANK YOU
Trials in npx
Trials in npx
Trials in npx
Trials in npx

More Related Content

Trials in npx

  • 1. NPC Treatment and clinical Trials Nasopharyngeal carcinoma is an uncommon cancer in most parts of the world. The age- adjusted incidence rate (per 100,000 people per year) among men ranges from 0.6 in the United States and Japan to 5.4 in Algeria, 5.8 in the Philippines,11.0 in Singapore, 17.2 among Eskimos, Indians, and Aleuts in Alaska to 17.8 and 26.9 in Hong Kong and Guangdong Province in Southern China, respectively.
  • 2. Because of the anatomic locationproximity to critical structures surgical exposure and tumor resection with sufficient margins have been very challenging. Primary surgical intervention was rare after the 1950s for these reasons, with surgical interventions employed mainly for biopsy to gain histologic confirmation and salvage therapy for persistent or recurrent cancer. Primary treatment since has typically employed radiotherapy (RT) alone and, more recently, in combination with chemotherapy.
  • 48. A previous individual patient data meta- analysis by the Meta-Analysis of Chemotherapy in Nasopharynx Carcinoma (MAC-NPC) collaborative group to assess the addition of chemotherapy to radiotherapy showed that it improves overall survival in nasopharyngeal carcinoma. This benefit was restricted to patients receiving concomitant chemotherapy and radiotherapy
  • 49. The aim of this study was to update the meta-analysis, include recent trials, and to analyse separately the benefit of concomitant plus adjuvant chemotherapy
  • 50. Survival curves for overall survival in trials investigating CRT,and CRT Plus ACT
  • 51. Survival curves for PFS in trials investigating CRT and CRT plus ACT
  • 52. Survival curves for (A) OS and (B) PFS in CCRT And CCRT And ACT
  • 53. conclusion this individual patient data meta-analysis confirms the benefits associated with the addition of chemotherapy to radiotherapy in nasopharyngeal carcinoma; the greatest benefit was found in the groups with concomitant administration. The benefits of the addition of adjuvant chemotherapy in the context of concomitant chemo-radiation still need further assessment.